British Journal of Anaesthesia, 2003, Vol. 91, No. 4 566-576
© 2003 The Board of Management and Trustees of the British Journal of Anaesthesia
Review Article |
Anaesthetics and cardiac preconditioning. Part II. Clinical implications
1 Institute of Anaesthesiology, University Hospital Zurich, Zurich, Switzerland. 2 Department of Anaesthesiology, University of Lausanne, Lausanne, Switzerland. 3 Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
Corresponding author: Institute of Anaesthesiology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland. E-mail: michael.zaugg@usz.ch
Abstract
There is compelling evidence that preconditioning occurs in humans. Experimental studies with potential clinical implications as well as clinical studies evaluating ischaemic, pharmacological and anaesthetic cardiac preconditioning in the perioperative setting are reviewed. These studies reveal promising results. However, there are conflicting reports on the efficacy of preconditioning in the diseased and aged myocardium. In addition, many anaesthetics and a significant number of perioperatively administered drugs affect the activity of cardiac sarcolemmal and mitochondrial KATP channels, the end-effectors of cardiac preconditioning, and thereby markedly modulate preconditioning effects in myocardial tissue. Although these modulatory effects on KATP channels have been investigated almost exclusively in laboratory investigations, they may have potential implications in clinical medicine. Important questions regarding the clinical utility and applicability of perioperative cardiac preconditioning remain unresolved and need more experimental work and randomized controlled clinical trials.
Br J Anaesth 2003; 91: 566–76
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. W. Sturesson, A. Johansson, M. Bodelsson, and G. Malmkvist Wash-in kinetics for sevoflurane using a disposable delivery system (AnaConDa(R)) in cardiac surgery patients Br. J. Anaesth., April 1, 2009; 102(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, X. Zhang, B. Zhu, and Z. Xue Desflurane Preconditioning Inhibits Endothelial Nuclear Factor-{kappa}-B Activation by Targeting the Proximal End of Tumor Necrosis Factor-{alpha} Signaling Anesth. Analg., May 1, 2008; 106(5): 1473 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Feng, E. Lucchinetti, G. Fischer, M. Zhu, K. Zaugg, M. C. Schaub, and M. Zaugg Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1{alpha} and CREB Cardiovasc Res, April 1, 2008; 78(1): 98 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lucchinetti, M. Jamnicki, G. Fischer, and M. Zaugg Preconditioning by Isoflurane Retains Its Protection Against Ischemia-Reperfusion Injury in Postinfarct Remodeled Rat Hearts Anesth. Analg., January 1, 2008; 106(1): 17 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zaugg Is protection by inhalation agents volatile? Controversies in cardioprotection Br. J. Anaesth., November 1, 2007; 99(5): 603 - 606. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Walsh, T. Tang, U. Sadat, D. P. Dutka, and M. E. Gaunt Cardioprotection by remote ischaemic preconditioning Br. J. Anaesth., November 1, 2007; 99(5): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Deyhimy, N. W. Fleming, I. G. Brodkin, and H. Liu Anesthetic Preconditioning Combined with Postconditioning Offers No Additional Benefit Over Preconditioning or Postconditioning Alone Anesth. Analg., August 1, 2007; 105(2): 316 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Annecke, J. C. Kubitz, S. Kahr, J. M. Hilberath, K. Langer, G. I. Kemming, M. Rehm, I. Bittmann, and P. F. Conzen Effects of sevoflurane and propofol on ischaemia-reperfusion injury after thoracic-aortic occlusion in pigs Br. J. Anaesth., May 1, 2007; 98(5): 581 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Riksen, Z. Zhou, W. J.G. Oyen, R. Jaspers, B. P. Ramakers, R. M.H.J. Brouwer, O. C. Boerman, N. Steinmetz, P. Smits, and G. A. Rongen Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning J. Am. Coll. Cardiol., August 15, 2006; 48(4): 700 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Hett Anaesthesia for off-pump coronary artery surgery CEACCP, April 1, 2006; 6(2): 60 - 62. [Full Text] [PDF]
|
|
|
|
|
|
M. Lutz and H. Liu Inhaled sevoflurane produces better delayed myocardial protection at 48 versus 24 hours after exposure. Anesth. Analg., April 1, 2006; 102(4): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Bovill Intravenous Anesthesia for the Patient with Left Ventricular Dysfunction Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2006; 10(1): 43 - 48. [Abstract] [PDF]
|
|
|
|
|
|
E. Lucchinetti, R. da Silva, T. Pasch, M. C. Schaub, and M. Zaugg Anaesthetic preconditioning but not postconditioning prevents early activation of the deleterious cardiac remodelling programme: evidence of opposing genomic responses in cardioprotection by pre- and postconditioning Br. J. Anaesth., August 1, 2005; 95(2): 140 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Garcia, K. Julier, L. Bestmann, A. Zollinger, L. K. von Segesser, T. Pasch, D. R. Spahn, and M. Zaugg Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery Br. J. Anaesth., February 1, 2005; 94(2): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. da Silva, E. Lucchinetti, T. Pasch, M. C. Schaub, and M. Zaugg Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium Physiol Genomics, December 15, 2004; 20(1): 117 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Magner and D. Royston Heart failure Br. J. Anaesth., July 1, 2004; 93(1): 74 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zaugg, M. C. Schaub, and P. Foex Myocardial injury and its prevention in the perioperative setting Br. J. Anaesth., July 1, 2004; 93(1): 21 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Riess, D. F. Stowe, and D. C. Warltier Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1603 - H1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Spahn and H.-J. Priebe Editorial II: Preoperative hypertension: remain wary? 'Yes'--cancel surgery? 'No' Br. J. Anaesth., April 1, 2004; 92(4): 461 - 464. [Full Text] [PDF]
|
|
|
|
|
|
P.-G. Chassot, P. van der Linden, M. Zaugg, X. M. Mueller, and D. R. Spahn Off-pump coronary artery bypass surgery: physiology and anaesthetic management{dagger} Br. J. Anaesth., March 1, 2004; 92(3): 400 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zaugg, E. Lucchinetti, M. Uecker, T. Pasch, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms Br. J. Anaesth., October 1, 2003; 91(4): 551 - 565. [Abstract] [Full Text] [PDF]
|
|